Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis

Inflammation Research

Volumn 58, Issue 7, 2009, Pages 413-421

  Markel, David C ^a   Zhang, Renwen ^c   Shi, Tong ^b   Hawkins, Monica ^c   Ren, Weiping ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wayne State University   (United States)

^c Stryker Orthopaedics   (United States)

Author keywords

Animal model; Erythromycin; Osteoclastogenesis; Osteolysis; VEGF; Wear debris

Indexed keywords

ANTIINFLAMMATORY AGENT; ERYTHROMYCIN; FLT1 PROTEIN, MOUSE; INTERLEUKIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; POLYETHYLENE DERIVATIVE; SODIUM CHLORIDE; TNFSF11 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE; ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MOUSE; OSTEOLYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; ERYTHROMYCIN; FEMALE; GENE EXPRESSION REGULATION; INTERLEUKIN-1; MICE; MICE, INBRED BALB C; OSTEOLYSIS; POLYETHYLENES; RANK LIGAND; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84871889298     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-009-0007-9     Document Type: Article

References (43)

1. Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am. 2002;84(2):171-7. (Pubitemid 37127476)
2. Al Saffar N, Mah JT, Kadoya Y, Revell PA. Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants. Ann Rheum Dis. 1995;54(3):201-8.
3. Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact. 2004;4(3):276-84. (Pubitemid 39504355)
4. Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999;190(2):293-8. (Pubitemid 29354921)
5. Kaku M, Kohno S, Kawata T, Fujita I, Tokimasa C, Tsutsui K, et al. Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice. J Dent Res. 2001;80(10):1880-3. (Pubitemid 33038054)
6. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 2000;473(2):161-4. (Pubitemid 30254282)
7. Jell GMR, Al-Saffar N. Does a pro-angiogenic state exist in the bone-implant interface of aseptically loosened joint prosthesis? J Mater Sci: Mater Med. 2001;12:1069-73. (Pubitemid 34062138)
8. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269(43):26988-95. (Pubitemid 24332901)
9. Ren WP, Yang S, Wooley PH. A novel murine model of orthopaedic wear debris-associated osteolysis. Scand J Rheumatol. 2004;33:349-57. (Pubitemid 39421221)
10. Ren W, Zhang R, Markel DC, Wu B, Peng X, Hawkins M, et al. Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis. J Rheumatol. 2007;34(1):27-35. (Pubitemid 46106559)
11. Ren WP, Markel DC, Zhang R, Peng X, Wu B, Monica H, et al. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials. 2006;27(30):5161-9. (Pubitemid 44080291)
12. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117(3):393-405.
13. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31(1):12-20. (Pubitemid 350236720)
14. Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121(1):83-92. (Pubitemid 32205030)
15. Ren WP, Bin W, Mayton L, Wooley PH. Erythromycin (EM) inhibits wear debris-induced inflammatory osteolysis in a murine model. J Orthop Res. 2006;24:280-90. (Pubitemid 43773039)
16. Ren WP, Li XY, Chen BD, Wooley PH. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NFkB activity. J Orthop Res. 2004;22:21-9. (Pubitemid 38035441)
17. Meghari S, Rolain JM, Grau GE, Platt E, Barrassi L, Mege JL, et al. Antiangiogenic effect of erythromycin: an in vitro model of Bartonella quintana infection. J Infect Dis. 2006;193(3):380-6. (Pubitemid 43122337)
18. Yatsunami J, Hayashi S. Fourteen-membered ring macrolides as anti-angiogenic compounds. Anticancer Res. 2001;21(6B):4253-8. (Pubitemid 34240956)
19. Bi Y, van de Motter RR, Ragab AA, Goldberg VM, Greenfield EM. The role of adherent endotoxin in stimulation of osteoclast differentiation by orthopaedic wear particles. Trans Orthop Res Soc. 1999;45:5.
20. Wooley PH, Morren R, Andary J, Sud S, Yang SY, Mayton L, et al. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials. 2002;23(2):517-26. (Pubitemid 33051040)
21. Ren WP, Wu B, Mayton L, Wooley PH. Polyethylene and methyl methacrylate particle-stimulated inflammatory tissue and macrophages up-regulate bone resorption in a murine neonatal bone resorption in a murine neonatal calvaria in vitro organ system. J Orthop Res. 2002;20:1031-7.
22. Yang SY, Ren W, Park Y, Sieving A, Hsu S, Nasser S, et al. Diverse cellular and apoptotic responses to variant shapes of UHMWPE particles in a murine model of inflammation. Biomaterials. 2002;23(17):3535-43. (Pubitemid 34626557)
23. Miyanishi K, Trindade MC, Ma T, Goodman SB, Schurman DJ, Smith RL. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles. J Bone Miner Res. 2003;18(9):1573-83. (Pubitemid 37022915)
24. Gallo J, Kaminek P, Ticha V, Rihakova P, Ditmar R. Particle disease. A comprehensive theory of periprosthetic osteolysis: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2002;146(2):21-8.
25. Jones LC, Frondoza C, Hungerford DS. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res. 1999;48(6):889-98.
26. Goodsell DS. The molecular perspective: VEGF and angiogenesis. Oncologist. 2002;7(6):569-70. (Pubitemid 36009004)
27. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol. 2000;191(4):426-33. (Pubitemid 30649912)
28. De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol. 2003;171(9):4853-9. (Pubitemid 37310607)
29. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 1994;180 (1):341-6. (Pubitemid 24181082)
30. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P, et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 2004;104(4):1048-57. (Pubitemid 39038025)
31. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 2003;48(8):2173-7. (Pubitemid 36959197)
32. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003;102(1):161-8. (Pubitemid 36759650)
33. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci. 2002;979:80-93. (Pubitemid 36121141)
34. Ben Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372(1):83-7.
35. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41(7):1258-65. (Pubitemid 28313429)
36. Kato T, Haro H, Komori H, Shinomiya K. Sequential dynamics of inflammatory cytokine, angiogenesis inducing factor and matrix degrading enzymes during spontaneous resorption of the herniated disc. J Orthop Res. 2004;22(4):895-900. (Pubitemid 38756275)
37. Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem. 2003;278(41):39548-57. (Pubitemid 37248513)
38. Kodama I, Niida S, Sanada M, Yoshiko Y, Tsuda M, Maeda N, et al. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. J Bone Miner Res. 2004;19(2):200-6. (Pubitemid 38116733)
39. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001;97(3):785-91. (Pubitemid 32113414)
40. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998;101(1):40-50. (Pubitemid 28058901)
41. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res. 2001;16(2):338-47. (Pubitemid 32105415)
42. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336-43. (Pubitemid 26115364)
43. Matsumoto Y, Tanaka K, Hirata G, Hanada M, Matsuda S, Shuto T, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol. 2002;168(11):5824-31. (Pubitemid 34556170)